Shire to buy FerroKin for up to $325m bringing in iron chelator candidate
This article was originally published in Scrip
Shire is buying privately-held US biotech company FerroKin BioSciences for $100 million up front and $225 million in milestones as a "strategic step in building its haematology business". FerroKin brings a "differentiated" development candidate to Shire's portfolio, the Phase II-stage iron chelator FBS0701, it added.
You may also be interested in...
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.